Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
Background: Mesalazine is among the medications most prescribed by gastroenterologists, with variable and controversial use in different settings. We aimed to explore the use of mesalazine in the clinical practice of young gastroenterologists. Methods: A web-based electronic survey was distributed t...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/5/2005 |
| _version_ | 1797614997204893696 |
|---|---|
| author | Olga Maria Nardone Giovanni Marasco Loris Riccardo Lopetuso Giammarco Mocci Luca Pastorelli Carlo Petruzzellis Franco Scaldaferri on behalf of the Italian Association of Young Gastroenterologist and Endoscopist (AGGEI) |
| author_facet | Olga Maria Nardone Giovanni Marasco Loris Riccardo Lopetuso Giammarco Mocci Luca Pastorelli Carlo Petruzzellis Franco Scaldaferri on behalf of the Italian Association of Young Gastroenterologist and Endoscopist (AGGEI) |
| author_sort | Olga Maria Nardone |
| collection | DOAJ |
| description | Background: Mesalazine is among the medications most prescribed by gastroenterologists, with variable and controversial use in different settings. We aimed to explore the use of mesalazine in the clinical practice of young gastroenterologists. Methods: A web-based electronic survey was distributed to all participants of the National Meeting of the Italian Young Gastroenterologist and Endoscopist Association. Results: A total of 101 participants took part in the survey, with a majority (54.4%) being aged >30 years, 63.4% of whom were trainees in academic hospitals, and 69.3% of whom were involved in the clinical management of inflammatory bowel disease (IBD). While both non-dedicated and IBD physicians generally agreed on the appropriate dose of mesalazine for mild ulcerative colitis (UC), significant differences were observed between the two groups for moderate-severe ulcerative colitis (UC). Additionally, in IBD patients who were starting immuno-modulators and/or biologics, 80% of IBD-dedicated physicians continued to prescribe mesalazine, compared to 45.2% of non-dedicated physicians (<i>p</i> = 0.002). Indeed, 48.4% of non-dedicated IBD physicians did not acknowledge mesalazine for colorectal cancer chemoprevention. With regards to Crohn’s disease, it is mainly used by 30.1% of IBD physicians for preventing postoperative recurrence of Crohn’s disease. Finally, 57.4% used mesalazine for symptomatic uncomplicated diverticular disease, and 84.2% did not recommend its use for irritable bowel syndrome. Conclusions: This survey showed heterogeneous behaviors in the daily use of mesalazine, mainly in the management of IBD. Educational programs and novel studies are needed to clarify its use. |
| first_indexed | 2024-03-11T07:20:13Z |
| format | Article |
| id | doaj.art-0b732aad841c4ddd8f2deb6af6bb9559 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T07:20:13Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-0b732aad841c4ddd8f2deb6af6bb95592023-11-17T08:01:19ZengMDPI AGJournal of Clinical Medicine2077-03832023-03-01125200510.3390/jcm12052005Insights into Mesalazine Use in Clinical Practice of Young GastroenterologistsOlga Maria Nardone0Giovanni Marasco1Loris Riccardo Lopetuso2Giammarco Mocci3Luca Pastorelli4Carlo Petruzzellis5Franco Scaldaferri6on behalf of the Italian Association of Young Gastroenterologist and Endoscopist (AGGEI)Gastroenterology, Department of Public Health, University Federico II of Naples, 80131 Naples, ItalyDivision of Internal Medicine and Digestive Physiopathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola, 40138 Bologna, ItalyCEMAD—IBD UNIT—Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Gastroenterologiche, Endocrino-Metaboliche e Nefro-Urologiche, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, 00168 Rome, ItalyDivision of Gastroenterology, “Brotzu” Hospital, 09124 Cagliari, ItalyGastroenterology and Hepatology Unit, ASST Santi Paolo e Carlo, 20142 Milan, ItalyGastroenterology Unit, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, 95123 Catania, ItalyCEMAD—IBD UNIT—Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Gastroenterologiche, Endocrino-Metaboliche e Nefro-Urologiche, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, 00168 Rome, ItalyBackground: Mesalazine is among the medications most prescribed by gastroenterologists, with variable and controversial use in different settings. We aimed to explore the use of mesalazine in the clinical practice of young gastroenterologists. Methods: A web-based electronic survey was distributed to all participants of the National Meeting of the Italian Young Gastroenterologist and Endoscopist Association. Results: A total of 101 participants took part in the survey, with a majority (54.4%) being aged >30 years, 63.4% of whom were trainees in academic hospitals, and 69.3% of whom were involved in the clinical management of inflammatory bowel disease (IBD). While both non-dedicated and IBD physicians generally agreed on the appropriate dose of mesalazine for mild ulcerative colitis (UC), significant differences were observed between the two groups for moderate-severe ulcerative colitis (UC). Additionally, in IBD patients who were starting immuno-modulators and/or biologics, 80% of IBD-dedicated physicians continued to prescribe mesalazine, compared to 45.2% of non-dedicated physicians (<i>p</i> = 0.002). Indeed, 48.4% of non-dedicated IBD physicians did not acknowledge mesalazine for colorectal cancer chemoprevention. With regards to Crohn’s disease, it is mainly used by 30.1% of IBD physicians for preventing postoperative recurrence of Crohn’s disease. Finally, 57.4% used mesalazine for symptomatic uncomplicated diverticular disease, and 84.2% did not recommend its use for irritable bowel syndrome. Conclusions: This survey showed heterogeneous behaviors in the daily use of mesalazine, mainly in the management of IBD. Educational programs and novel studies are needed to clarify its use.https://www.mdpi.com/2077-0383/12/5/2005mesalazineinflammatory bowel diseaseulcerative colitissurveytrainingeducational program |
| spellingShingle | Olga Maria Nardone Giovanni Marasco Loris Riccardo Lopetuso Giammarco Mocci Luca Pastorelli Carlo Petruzzellis Franco Scaldaferri on behalf of the Italian Association of Young Gastroenterologist and Endoscopist (AGGEI) Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists Journal of Clinical Medicine mesalazine inflammatory bowel disease ulcerative colitis survey training educational program |
| title | Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists |
| title_full | Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists |
| title_fullStr | Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists |
| title_full_unstemmed | Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists |
| title_short | Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists |
| title_sort | insights into mesalazine use in clinical practice of young gastroenterologists |
| topic | mesalazine inflammatory bowel disease ulcerative colitis survey training educational program |
| url | https://www.mdpi.com/2077-0383/12/5/2005 |
| work_keys_str_mv | AT olgamarianardone insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists AT giovannimarasco insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists AT lorisriccardolopetuso insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists AT giammarcomocci insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists AT lucapastorelli insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists AT carlopetruzzellis insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists AT francoscaldaferri insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists AT onbehalfoftheitalianassociationofyounggastroenterologistandendoscopistaggei insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists |